Doeblin, Patrick http://orcid.org/0000-0002-1511-8015
Jahnke, Constantin
Schneider, Matthias
Al-Tabatabaee, Sarah
Goetze, Collin
Weiss, Karl J.
Tanacli, Radu
Faragli, Alessandro
Witt, Undine
Stehning, Christian
Seidel, Franziska
Elsanhoury, Ahmed
Kühne, Titus
Tschöpe, Carsten
Pieske, Burkert
Kelle, Sebastian
Funding for this research was provided by:
Deutsches Herzzentrum Berlin
Article History
Received: 22 February 2022
Accepted: 15 April 2022
First Online: 12 May 2022
Declarations
:
: PD owns stock of Siemens and Bayer. AF is a shareholder of BOCAhealthcare GmbH. CS is an employer of Philips Healthcare. BP reported receiving personal fees from Bayer, Bristol Myers Squib, Daiichi Sankyo, Medscape, MSD, Novartis, Stealth Peptides, and Vifor Pharma, and grants and personal fees from Astra-Zeneca. CT, BP and SK received funding from the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) and personal fees from Servier, outside of the current work. SK received an unrestricted research grant from Philips Healthcare and received lecture honoraria from Medis, NL.
: The study complies with the declaration of Helsinki and was approved by the ethics committee of the Charité-Universitätsmedizin Berlin (EA2/020/21) as a retrospective analysis with a waiver of consent.
: Consent for publication has been obtained from all patients with individual data.